Profound Medical Corp. Earnings Per Share Disclosure
14 | Loss per share |
The following table shows the calculation of basic and diluted loss per share:
| 2025 | | 2024 | ||||
Net loss for the year |
| $ | 42,570 |
| $ | 27,816 |
|
Weighted average number of common shares |
| 30,232,966 |
| 24,765,503 |
| ||
Basic and diluted loss per share |
| $ | 1.41 |
| $ | 1.12 |
|
The computation of diluted loss per share is equal to the basic loss per share due to the anti-dilutive effect of the share options, RSUs and DSUs. Of the 2,142,522 (2024 – 2,291,152) share options, 859,335 (2024 – 324,621) RSUs, and 135,490 (2024 – 91,670) DSUs not included in the calculation of diluted loss per share for the year ended December 31, 2025, 1,409,262 (2024 – 1,326,573) were exercisable.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 5, 2026 | Showing above |
| 2024 | Mar 7, 2025 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.